Eleanor Howe is a computational biologist with deep knowledge of the drug discovery and development processes. Diamond Age builds on Howe’s expertise in transcriptional profiling, a field in which she has worked since from its early days of small-scale microarray analysis.
Prior to founding Diamond Age, Howe served as the go-to bioinformatician in the Center for the Development of Therapeutics at the Broad Institute of MIT and Harvard, where she helped drive drug discovery projects in cancer, cardiovascular disease, and kidney disease, among others. She has also worked at the Dana-Farber Cancer Institute, where she led mid- and late-stage development of the Multiexperiment Viewer – a powerful software tool for mining large genomic datasets – and the Institute for Genomic Research in Rockville, Maryland.
Howe earned a Ph.D. bioinformatics from Oxford University under Christopher Holmes and John Quackenbush, and holds a master’s degree in cellular and molecular biology from the University of Wisconsin-Madison and a bachelor’s degree in cellular and molecular biology from the University of Michigan. You can read her published scientific work here.
Why “Diamond Age?”
We live in a world in which molecular technology is transforming all aspects of life. So do the protagonists of Neal Stephenson’s futuristic and acclaimed fourth novel, “The Diamond Age: Or, A Young Lady’s Illustrated Primer,” an ode to the importance of innovation and the value of knowledge. The diamond age is what follows the information age — after we learn to manage information, mine our data, and turn that data into knowledge (and, in the case of the book, build skyscrapers from diamonds). The company is named in tribute.